For over 30 years, Cepheid has been committed to A Better Way in molecular diagnostics—bringing clinicians and lab directors the answers they need through the GeneXpert® system and our expanding respiratory menu. And soon, there’s more on the way for respiratory testing. Stay tuned for what’s next. A Better Way to the answers that matter is coming. https://ow.ly/70ns50YUBGG #DiagnosticExcellence #HealthcareInnovation #ComingSoon #PatientOutcomes #MedicalDiagnostics #SmartAnswers
About us
Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid’s broad test portfolio spans respiratory infections, blood virology, women’s and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company’s solutions deliver actionable results where they are needed most – from central laboratories and hospitals to near-patient settings. For more information, visit http://www.cepheid.com. Cepheid is proud to be a part of Danaher. Danaher’s science and technology leadership puts Cepheid’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics, and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.
- Website
-
http://www.cepheid.com
External link for Cepheid
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Sunnyvale, CA
- Type
- Public Company
- Founded
- 1996
- Specialties
- Molecular Diagnostics, Genetic Testing, Molecular Biology, Infectious Diseases, Cancer, and PCR
Locations
-
Primary
Get directions
904 Caribbean Drive
Sunnyvale, CA 94089, US
-
Get directions
Vira Solelh
Maurens-Scopont, 81470, FR
-
Get directions
Aston Court
Kingsmead Business Park, Frederick Place
High Wycombe, Buckinghamshire HP11 1LA, GB
-
Get directions
Röntgenv 2
Solna, 171 54, SE
Employees at Cepheid
Updates
-
We’re excited to be at APHL 2026 in Baltimore, MD! Stop by booth #217 at the Baltimore Convention Center to explore how Cepheid delivers Smart Answers with efficient workflows, diagnostic confidence, and a flexible molecular platform designed for today’s public health challenges. #AntimicrobialStewardship #APHL2026 Learn More: https://ow.ly/IBOM50YTGeb
-
-
💡Brock Schroeder bridges strategy and healthcare to advance market access—ensuring diagnostics reach patients through strong clinical and economic evidence. His leadership is opening doors to a more accessible future in molecular testing. Read more about Brock at: https://lnkd.in/gjG8-dNh ✨At Cepheid, innovation meets impact. We turn cutting-edge diagnostics into accessible solutions—making it a place where your work truly improves lives.
-
-
🏆That’s a wrap on Cepheid’s 2026 CEO & President’s Kaizen in Solna, Sweden—an energizing milestone within the broader 2026 Danaher CEO Kaizen, spanning six countries and 21 cities. 📆 Over the course of this week, teams came together at Gemba to apply a true race‑car mindset: speed, precision, and disciplined execution in pursuit of real, measurable improvements. From manufacturing excellence to operational innovation, the focus on Continuous Improvement was unmistakable—and deeply inspiring. ⚡️For 30 years, Cepheid has believed that behind every cartridge is a patient. That belief was front and center this week, guiding every discussion, insight, and breakthrough as we worked toward “A Better Way” in molecular diagnostics. Thank you to our global colleagues and leaders who brought passion, expertise, and even a little fun to the work. The momentum we’ve built in Solna will carry forward as we continue racing toward results—Always Onward. #Bestteamwins #Kaizen #DBS #ContinuousImprovement
-
-
🧬Genomic sequencing can unlock powerful insights, but those insights are not always within reach for laboratories. Cepheid and Oxford Nanopore Technologies are working together to change that. 👉 Learn more about this collaboration and how it’s helping make genomic sequencing more practical: http://cepheid.com/seq #InfectiousDiseaseResearch #Genomics #Partnership
-
Cepheid reposted this
Top Take-Aways from ESCMID 2026 What are the top take-aways from ESCMID - European Society of Clinical Microbiology and Infectious Diseases 2026? With so much strong science presented in Munich, that’s a challenging question to answer! I’ve been thinking a lot about moving diagnostic stewardship from a vision to reality – notably, the practical considerations that hinder stewardship programs and how a ‘Goldilocks approach’ is warranted. Through that lens, a few themes stood out: Enabling care, everywhere: This year I sensed a greater focus on and urgency to the discussion around enabling diagnostics for decentralized care. I wholeheartedly support this uptick. Given Cepheid’s testing philosophy and offerings supporting ‘care, everywhere’ (e.g., TB, vaginitis, Group A Strep, COVID, etc.) I’m particularly encouraged by the dialogue around rapid diagnostics and innovative service delivery outside traditional hospital laboratories. Making NGS accessible: There was lots of conversation regarding Next-Generation Sequencing (NGS) for rapid pathogen diagnostics, surveillance, and antimicrobial resistance (AMR) detection. While the buzz around NGS isn’t new, what is new is the shift from talking about what may be possible to talking about implementing NGS – a challenge Cepheid is addressing through our expanded partnership with Oxford Nanopore Technologies addressing NGS in workflows. AMR in the spotlight: Antimicrobial resistance (AMR) remains a dominant topic at the congress, and rightfully so. This year saw more dialogue around strategies to combat AMR. Cepheid is in the thick of this effort, as evidenced by our ongoing work with the Fleming Initiative and our offerings to guide infection control-- including our pipeline aimed at addressing hospital-associated C. auris. Thank you for the opportunity to connect in Munich. For others who attended ESCMID this year, wondering what grabbed your attention? ##ESCMID2026 #Diagnosticstewardship #infectiousdiease
-
-
🏆 Cepheid is proud to serve as a Champion for the 2026 PRI Innovation Forum: Empowering Hyperlocal Response, hosted by the NYC Preparedness & Recovery Institute (PRI) in partnership with Columbia Engineering, coming up on May 5th in NYC. 🤝The day brings together researchers, government, industry, community-based organizations, technologists, funders, and social entrepreneurs to move from exploration to execution, with a clear focus on strengthening sustainable partnerships and advancing solutions that can scale to support New York City’s long-term public health resilience. 📆 Register and learn more: https://ow.ly/iw0H50YBWA6 #PublicHealth #Preparedness #NYC #Innovation #CommunityResilience
-
-
We’re excited to be at APHL 2026 in Baltimore, MD! Stop by booth #217 at the Baltimore Convention Center to explore how Cepheid delivers Smart Answers with efficient workflows, diagnostic confidence, and a flexible molecular platform designed for today’s public health challenges. #AntimicrobialStewardship #APHL2026 Learn More: https://lnkd.in/gY6nfi7T
-
-
Cepheid is honored to partner with the Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND) in support of the Next Generation Diagnostics System 2 – Man Portable Diagnostic System (NGDS 2 MPDS) program. As part of this effort, the Xpert® Hemorrhagic Fever test on the GeneXpert® Edge X system supports the detection of key viral threats relevant to the NGDS 2 MPDS mission. We appreciate the opportunity to contribute molecular diagnostic capabilities that help enable early, informed responses in support of this program. *Xpert® Hemorrhagic Fever test on the GeneXpert® Edge X system supports the NGDS 2 MPDS program. Not commercially available.
Big wins for our Next Generation Diagnostics System 2 – Man Portable Diagnostic System (NGDS 2 MPDS) program!🙌The NGDS 2 MPDS will provide a rapid, man-portable diagnostic capability that supports early warning and effective response to biological threats. Congrats to our Joint Project Manager for CBRN Medical team on the following wins: 1️⃣Users from the US Army, US Navy, United States Air Force, and USSOCOM completed a successful Operational User Evaluation for the NGDS 2 MPDS at the Air Force Medical Service's Air Force Medical Command. This is an important step toward getting this technology into warfighters' hands. 2️⃣Our partners at Cepheid received FDA 510(k) clearance for the Xpert® Hemorrhagic Fever test on the GeneXpert® Edge X (part of the NGDS 2 MPDS). This clearance paves the way for fielding this year. Way to go team!👏 #CPECBRND #Medical
-
-
📍 Join us at ACOG 2026 for an educational session you won’t want to miss! 🗓 Friday, May 1 ⏰ 2:35–3:05 PM 📌 Exhibit Hall – Theater 2 From Wet Mount to NAAT Point of Care: Getting Vaginitis Diagnosis and Treatment RIGHT This session explores the evolution from traditional wet mount methods to NAAT point-of-care testing, and how modern diagnostics can improve accuracy and support more informed treatment decisions in vaginitis care. We hope to see you there—then continue the conversation at ACOG 2026 Booth #1015.#ACOG2026 #WomensHealth #VaginitisCare #PointOfCare #MolecularDiagnostics
-